VIVEbiotech adds newest in vivo lentiviral vector-based therapeutic programs 10/06/2026 Healthcare Innovative drugs Advanced therapies Now advancing 15 next-generation in vivo therapies through high performance, scalable lentiviral vector manufacturing... Partners - VIVEbiotech
BCN HEALTH publishes a study evaluating the incidence and medical cost associated to intra... 03/06/2026 Healthcare Innovative drugs Personalized medicine Partners - BCN Health
ORYZON initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential t... 02/06/2026 Healthcare Drug discovery Innovative drugs Oryzon Genomics, a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the... Partners - Oryzon Genomics
BioClonal seeks strategic partnerships to advance its Alzheimer’s antibody program and ant... 02/06/2026 Healthcare Access to innovation Drug discovery Innovative drugs Spanish biotechnology company BioClonal is advancing a proprietary monoclonal antibody program targeting a novel... Partners - BIOCLONAL
World Multiple Sclerosis Day | “Biotechnology is enabling progress toward a better underst... 29/05/2026 Healthcare Innovative drugs Personalized medicine On the occasion of World Multiple Sclerosis Day, we interviewed Sanofi, which has a research line specifically focused... AseBio - SANOFI
Beyond Evidence: The Challenge of Communicating Value in Biotechnology 27/05/2026 Healthcare Access to innovation Innovative drugs Spain is already generating science and innovation in biotechnology. The next challenge is not to produce more evidence... Partners - ProductLife Group
MSD Strengthens Its R&D Leadership in Spain: Up 8% From the Previous Year, Reaching 209 Cl... 25/05/2026 Healthcare Access to innovation Innovative drugs The biomedical Company MSD, a leader in research, has reached a new milestone in its commitment to science and... Partners - MSD
Webinar NeuroTech Devices: Regulatory, Preclinical, and Clinical Insights Del 03/06/2026 17:00 to 03/06/2026 18:00 Healthcare Access to innovation Innovative drugs
ORYZON reports financial results and corporate update for quarter ended March 31st, 2026 19/05/2026 Healthcare Drug discovery Innovative drugs Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79%... Partners - Oryzon Genomics
VIVEbiotech and Zelluna Partnership to Advance Off-the Shelf TCR-NK Cell Therapy with GMP ... 19/05/2026 Healthcare Innovative drugs Advanced therapies Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo... Partners - VIVEbiotech
